(請注意 此堂課為課後複習，無積分登錄)

Adding platinum to neoadjuvant chemotherapy has been proved to increase the pCR rate in TNBC patients and the accompanying adverse effect is tolerable and manageable although the benefit of overall survival has not been well-established.

This lecture aims to present the efficacy and safety of various neoadjuvant regimens for patients diagnosed with early stage or locally advanced triple-negative breast cancer (TNBC).

Administration of docetaxel in a weekly schedule may offer similar efficacy, with a more favorable toxicity profile, compared to a three-weekly schedule in patients with breast cancer. 
This presentation will revisit Docetaxel schedule in early breast cancer & metastatic breast cancer. 

對於 HR+/HER2- MBC 的病人，不管是內生性或經過內分泌藥物治療後，所產生的賀爾蒙抗性是無法避免的，如何選擇下一階段治療的化療藥物，這將是當務之急… 

2022年11月10日(四)19:00-20:30，台灣乳房醫學會將於乳e學院線上直播，陳守棟理事長將為大家分享ESMO 2022的課程會議亮點!
歡迎您踴躍加入我的課程報名!

De-escalating anthracycline is gaining popularity for breast cancer patients.  This lecture aims to present the non-inferiority of an anthracycline-free regimen to the standard anthracycline- based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer and identify patients who are suitable for anthracycline-free regimen.